Luspatercept (Reblozyl)

luspatercept · Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc.

Drug timelines are a Plus or Pro feature.

3 regulatory and trial events tracked for Luspatercept (Reblozyl), covering 2024-07-29 to 2026-04-20. Get the full timeline:

Most recent: Clinical Trial Update: Luspatercept in Preventing Poor Erythroid Engraftment for Hematological Malignancies With Moderate to Severe Myelofibrosis [Phase 2, Phase 3]

See pricing